IXHL News and Press, Incannex Healthcare Limited From 02/28/24

2024-02-28 08:03:13 ET DENVER, Colo., Feb 28, 2024 ( 247marketnews.com )- Incannex Healthcare Inc. (NASDAQ: IXHL ) reported, this morning, positive topline results from its psilocybin in generalized anxiety disorder (GAD) Phase 2 Psi-GAD1 clinical trial, and that the trial met its p...

Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8 points from baseline, representing a 9.2-point improvement over psychotherapy with placebo (p <0.0001), exceeding the company...

A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...

2024-02-21 12:27:34 ET More on Mid-day movers & stocks. Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage Greenbrook TMS secures $1.5M in debt financing Compass Pathways and Greenbrook TMS enter into three-year research collabora...

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational N...

Highlights: Clarion’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. Clarion Clinics’ built-for-purpos...

MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for un...

Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia. Topline results from the trial anticipated within current Q1 2024. FDA IND application is well-advanced after commencing preparations in August, 2023. Independent docu...

MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine thera...

2023-12-28 12:33:33 ET Summary Incannex Healthcare Inc. is a developer of medicinal cannabinoid and psychedelic pharmaceutical products. Their strategy is to combine cannabinoid drugs with patent-expired therapeutic compounds for better therapeutic effects. They have several p...